{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T14:35:55Z","timestamp":1789050955851,"version":"build-2803163510"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,18]],"date-time":"2025-08-18T00:00:00Z","timestamp":1755475200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,18]],"date-time":"2025-08-18T00:00:00Z","timestamp":1755475200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Acute myeloid leukemia (AML) is an aggressive hematologic malignancy with a poor prognosis and limited therapeutic options. Leukemic stem cells (LSCs), which drive disease progression and confer resistance to therapy, pose a significant challenge to conventional treatment strategies. In this study, we identified and characterized the inhibitory mechanisms of TH37, a small molecule derived from traditional Chinese medicine, which selectively targets AML blasts and LSCs. Our analyses identified peroxiredoxin 1 (PRDX1), an enzyme that catalyzes the breakdown of hydrogen peroxide (a reactive oxygen species), as the primary molecular target of TH37. We demonstrated that TH37 directly interacts with PRDX1, inhibiting its enzymatic activity and thereby elevating intracellular reactive oxygen species levels in AML cells. PRDX1 was found to be overexpressed in AML, and its expression correlated with poor prognosis and the activation of AML- and cancer-associated pathways. Targeting PRDX1, either through lentiviral short-hairpin RNA-mediated silencing or TH37 treatment, induced apoptosis, reduced colony formation, and impaired the engraftment and growth of AML cells in immunodeficient mouse models. Furthermore, TH37 synergized with conventional chemotherapeutic agent to significantly reduce the viability and colony-forming capacity of AML cells. These findings demonstrate the critical role of PRDX1 in AML pathogenesis and highlight its potential as a key therapeutic target to improve clinical outcomes for AML patients.<\/jats:p>","DOI":"10.1038\/s41419-025-07831-6","type":"journal-article","created":{"date-parts":[[2025,8,18]],"date-time":"2025-08-18T18:24:29Z","timestamp":1755541469000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Targeting PRDX1 impairs acute myeloid leukemic blasts and stem cells by disrupting redox homeostasis"],"prefix":"10.1038","volume":"16","author":[{"given":"Zhenghao","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangci","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziren","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keming","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhe","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyu","family":"Ying","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danling","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengtian","family":"Tao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sajid","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yimeng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang-Lin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4118-362X","authenticated-orcid":false,"given":"Yun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingfeng","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6872-2665","authenticated-orcid":false,"given":"Li","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas J.","family":"Kipps","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongxian","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0564-895X","authenticated-orcid":false,"given":"Suping","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,18]]},"reference":[{"key":"7831_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2021.100829","volume":"49","author":"M de Lima","year":"2021","unstructured":"de Lima M, Roboz GJ, Platzbecker U, Craddock C, Ossenkoppele G. AML and the art of remission maintenance. Blood Rev. 2021;49:100829.","journal-title":"Blood Rev"},{"key":"7831_CR2","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00425-3","volume":"11","author":"H Kantarjian","year":"2021","unstructured":"Kantarjian H, Kadia T, DiNardo C, Daver N, Borthakur G, Jabbour E, et al. Acute myeloid leukemia: current progress and future directions. Blood Cancer J. 2021;11:41.","journal-title":"Blood Cancer J"},{"key":"7831_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.beha.2021.101248","volume":"34","author":"JM Rowe","year":"2021","unstructured":"Rowe JM. Perspectives on current survival and new developments in AML. Best Pr Res Clin Haematol. 2021;34:101248.","journal-title":"Best Pr Res Clin Haematol"},{"key":"7831_CR4","doi-asserted-by":"crossref","unstructured":"Stanchina M, Soong D, Zheng-Lin B, Watts JM, Taylor J. Advances in acute myeloid leukemia: recently approved therapies and drugs in development. Cancers. 2020;12.","DOI":"10.3390\/cancers12113225"},{"key":"7831_CR5","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.semcancer.2009.12.001","volume":"20","author":"SW Lane","year":"2010","unstructured":"Lane SW, Gilliland DG. Leukemia stem cells. Semin Cancer Biol. 2010;20:71\u20136.","journal-title":"Semin Cancer Biol"},{"key":"7831_CR6","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.3324\/haematol.2013.085209","volume":"99","author":"DA Pollyea","year":"2014","unstructured":"Pollyea DA, Gutman JA, Gore L, Smith CA, Jordan CT. Targeting acute myeloid leukemia stem cells: a review and principles for the development of clinical trials. Haematologica. 2014;99:1277\u201384.","journal-title":"Haematologica"},{"key":"7831_CR7","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1182\/blood-2016-10-696039","volume":"129","author":"DA Pollyea","year":"2017","unstructured":"Pollyea DA, Jordan CT. Therapeutic targeting of acute myeloid leukemia stem cells. Blood. 2017;129:1627\u201335.","journal-title":"Blood"},{"key":"7831_CR8","doi-asserted-by":"crossref","unstructured":"Arnone M, Konantz M, Hanns P, Paczulla Stanger AM, Bertels S, Godavarthy PS, et al. Acute myeloid leukemia stem cells: the challenges of phenotypic heterogeneity. Cancers. 2020;12.","DOI":"10.3390\/cancers12123742"},{"key":"7831_CR9","doi-asserted-by":"publisher","first-page":"2328","DOI":"10.1002\/ijc.26318","volume":"129","author":"EC Buss","year":"2011","unstructured":"Buss EC, Ho AD. Leukemia stem cells. Int J Cancer. 2011;129:2328\u201336.","journal-title":"Int J Cancer"},{"key":"7831_CR10","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1007\/s12185-017-2221-5","volume":"105","author":"D Hanekamp","year":"2017","unstructured":"Hanekamp D, Cloos J, Schuurhuis GJ. Leukemic stem cells: identification and clinical application. Int J Hematol. 2017;105:549\u201357.","journal-title":"Int J Hematol"},{"key":"7831_CR11","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1016\/j.arcmed.2003.08.007","volume":"34","author":"KJ Hope","year":"2003","unstructured":"Hope KJ, Jin L, Dick JE. Human acute myeloid leukemia stem cells. Arch Med Res. 2003;34:507\u201314.","journal-title":"Arch Med Res"},{"key":"7831_CR12","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1172\/JCI41495","volume":"121","author":"JE Sarry","year":"2011","unstructured":"Sarry JE, Murphy K, Perry R, Sanchez PV, Secreto A, Keefer C, et al. Human acute myelogenous leukemia stem cells are rare and heterogeneous when assayed in NOD\/SCID\/IL2Rgammac-deficient mice. J Clin Investig. 2011;121:384\u201395.","journal-title":"J Clin Investig"},{"key":"7831_CR13","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.ccr.2006.08.020","volume":"10","author":"TC Somervaille","year":"2006","unstructured":"Somervaille TC, Cleary ML. Identification and characterization of leukemia stem cells in murine MLL-AF9 acute myeloid leukemia. Cancer Cell. 2006;10:257\u201368.","journal-title":"Cancer Cell"},{"key":"7831_CR14","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-016-0574-7","volume":"16","author":"X Wang","year":"2017","unstructured":"Wang X, Huang S, Chen JL. Understanding of leukemic stem cells and their clinical implications. Mol Cancer. 2017;16:2.","journal-title":"Mol Cancer"},{"key":"7831_CR15","doi-asserted-by":"crossref","unstructured":"Bukowski K, Kciuk M, Kontek R. Mechanisms of multidrug resistance in cancer chemotherapy. Int J Mol Sci. 2020;21.","DOI":"10.3390\/ijms21093233"},{"key":"7831_CR16","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.2147\/OTT.S191621","volume":"12","author":"J Zhang","year":"2019","unstructured":"Zhang J, Gu Y, Chen B. Mechanisms of drug resistance in acute myeloid leukemia. Onco Targets Ther. 2019;12:1937\u201345.","journal-title":"Onco Targets Ther"},{"key":"7831_CR17","doi-asserted-by":"publisher","first-page":"4072","DOI":"10.4161\/cc.8.24.10242","volume":"8","author":"CA Neumann","year":"2009","unstructured":"Neumann CA, Cao J, Manevich Y. Peroxiredoxin 1 and its role in cell signaling. Cell Cycle. 2009;8:4072\u20138.","journal-title":"Cell Cycle"},{"key":"7831_CR18","doi-asserted-by":"publisher","first-page":"8038","DOI":"10.1038\/sj.onc.1208821","volume":"24","author":"RA Egler","year":"2005","unstructured":"Egler RA, Fernandes E, Rothermund K, Sereika S, de Souza-Pinto N, Jaruga P, et al. Regulation of reactive oxygen species, DNA damage, and c-Myc function by peroxiredoxin 1. Oncogene. 2005;24:8038\u201350.","journal-title":"Oncogene"},{"key":"7831_CR19","doi-asserted-by":"publisher","first-page":"139","DOI":"10.3892\/mco.2017.1129","volume":"6","author":"A Nicolussi","year":"2017","unstructured":"Nicolussi A, D\u2019Inzeo S, Capalbo C, Giannini G, Coppa A. The role of peroxiredoxins in cancer. Mol Clin Oncol. 2017;6:139\u201353.","journal-title":"Mol Clin Oncol"},{"key":"7831_CR20","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1111\/jcmm.12955","volume":"21","author":"C Ding","year":"2017","unstructured":"Ding C, Fan X, Wu G. Peroxiredoxin 1 - an antioxidant enzyme in cancer. J Cell Mol Med. 2017;21:193\u2013202.","journal-title":"J Cell Mol Med"},{"key":"7831_CR21","doi-asserted-by":"publisher","first-page":"4499","DOI":"10.1182\/blood-2011-02-336446","volume":"119","author":"R Godfrey","year":"2012","unstructured":"Godfrey R, Arora D, Bauer R, Stopp S, Muller JP, Heinrich T, et al. Cell transformation by FLT3 ITD in acute myeloid leukemia involves oxidative inactivation of the tumor suppressor protein-tyrosine phosphatase DEP-1\/ PTPRJ. Blood. 2012;119:4499\u2013511.","journal-title":"Blood"},{"key":"7831_CR22","doi-asserted-by":"publisher","first-page":"3873","DOI":"10.18632\/oncotarget.6763","volume":"7","author":"W Wei","year":"2016","unstructured":"Wei W, et al. Identification of H7 as a novel peroxiredoxin I inhibitor to induce differentiation of leukemia cells. Oncotarget. 2016;7:3873\u201383.","journal-title":"Oncotarget"},{"key":"7831_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2016.105","volume":"7","author":"E Panieri","year":"2016","unstructured":"Panieri E, Santoro MM. ROS homeostasis and metabolism: a dangerous liason in cancer cells. Cell Death Dis. 2016;7:e2253.","journal-title":"Cell Death Dis"},{"key":"7831_CR24","doi-asserted-by":"publisher","first-page":"3322","DOI":"10.1182\/blood-2013-04-491944","volume":"122","author":"PS Hole","year":"2013","unstructured":"Hole PS, Zabkiewicz J, Munje C, Newton Z, Pearn L, White P, et al. Overproduction of NOX-derived ROS in AML promotes proliferation and is associated with defective oxidative stress signaling. Blood. 2013;122:3322\u201330.","journal-title":"Blood"},{"key":"7831_CR25","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1186\/s13046-018-0797-0","volume":"37","author":"R Prieto-Bermejo","year":"2018","unstructured":"Prieto-Bermejo R, Romo-Gonzalez M, Perez-Fernandez A, Ijurko C, Hernandez-Hernandez A. Reactive oxygen species in haematopoiesis: leukaemic cells take a walk on the wild side. J Exp Clin Cancer Res. 2018;37:125.","journal-title":"J Exp Clin Cancer Res"},{"key":"7831_CR26","first-page":"3","volume":"44","author":"RZ Zhao","year":"2019","unstructured":"Zhao RZ, Jiang S, Zhang L, Yu ZB. Mitochondrial electron transport chain, ROS generation and uncoupling (Review). Int J Mol Med. 2019;44:3\u201315.","journal-title":"Int J Mol Med"},{"key":"7831_CR27","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/8127362","volume":"2019","author":"D Xian","year":"2019","unstructured":"Xian D, Lai R, Song J, Xiong X, Zhong J. Emerging perspective: role of increased ROS and redox imbalance in skin carcinogenesis. Oxid Med Cell Longev. 2019;2019:8127362.","journal-title":"Oxid Med Cell Longev"},{"key":"7831_CR28","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/j.devcel.2006.05.007","volume":"10","author":"HC Korswagen","year":"2006","unstructured":"Korswagen HC. Regulation of the Wnt\/beta-catenin pathway by redox signaling. Dev Cell. 2006;10:687\u20138.","journal-title":"Dev Cell"},{"key":"7831_CR29","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.ccell.2020.06.001","volume":"38","author":"JD Hayes","year":"2020","unstructured":"Hayes JD, Dinkova-Kostova AT, Tew KD. Oxidative stress in cancer. Cancer Cell. 2020;38:167\u201397.","journal-title":"Cancer Cell"},{"key":"7831_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.115036","volume":"165","author":"X Zhou","year":"2023","unstructured":"Zhou X, An B, Lin Y, Ni Y, Zhao X, Liang X. Molecular mechanisms of ROS-modulated cancer chemoresistance and therapeutic strategies. Biomed Pharmacother. 2023;165:115036.","journal-title":"Biomed Pharmacother"},{"key":"7831_CR31","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1038\/s12276-020-0384-2","volume":"52","author":"B Perillo","year":"2020","unstructured":"Perillo B, Di Donato M, Pezone A, Di Zazzo E, Giovannelli P, Galasso G, et al. ROS in cancer therapy: the bright side of the moon. Exp Mol Med. 2020;52:192\u2013203.","journal-title":"Exp Mol Med"},{"key":"7831_CR32","doi-asserted-by":"publisher","DOI":"10.1017\/erm.2018.3","volume":"20","author":"J Wang","year":"2018","unstructured":"Wang J, Wong YK, Liao F. What has traditional Chinese medicine delivered for modern medicine?. Expert Rev Mol Med. 2018;20:e4.","journal-title":"Expert Rev Mol Med"},{"key":"7831_CR33","doi-asserted-by":"publisher","first-page":"2100","DOI":"10.1038\/nprot.2014.138","volume":"9","author":"R Jafari","year":"2014","unstructured":"Jafari R, Almqvist H, Axelsson H, Ignatushchenko M, Lundback T, Nordlund P, et al. The cellular thermal shift assay for evaluating drug target interactions in cells. Nat Protoc. 2014;9:2100\u201322.","journal-title":"Nat Protoc"},{"key":"7831_CR34","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s13046-018-0756-9","volume":"37","author":"B Chen","year":"2018","unstructured":"Chen B, Lee JB, Kang H, Minden MD, Zhang L. Targeting chemotherapy-resistant leukemia by combining DNT cellular therapy with conventional chemotherapy. J Exp Clin Cancer Res. 2018;37:88.","journal-title":"J Exp Clin Cancer Res"},{"key":"7831_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41375-021-01416-w","volume":"36","author":"L de Beauchamp","year":"2022","unstructured":"de Beauchamp L, Himonas E, Helgason GV. Mitochondrial metabolism as a potential therapeutic target in myeloid leukaemia. Leukemia. 2022;36:1\u201312.","journal-title":"Leukemia"},{"key":"7831_CR36","doi-asserted-by":"publisher","DOI":"10.1186\/1476-4598-9-99","volume":"9","author":"W Suttana","year":"2010","unstructured":"Suttana W, Mankhetkorn S, Poompimon W, Palagani A, Zhokhov S, Gerlo S, et al. Differential chemosensitization of P-glycoprotein overexpressing K562\/Adr cells by withaferin A and Siamois polyphenols. Mol Cancer. 2010;9:99.","journal-title":"Mol Cancer"},{"key":"7831_CR37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.drup.2018.11.001","volume":"41","author":"Q Cui","year":"2018","unstructured":"Cui Q, Wang JQ, Assaraf YG, Ren L, Gupta P, Wei L, et al. Modulating ROS to overcome multidrug resistance in cancer. Drug Resist Updat. 2018;41:1\u201325.","journal-title":"Drug Resist Updat"},{"key":"7831_CR38","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1158\/0008-5472.CAN-09-1947","volume":"70","author":"TC Chou","year":"2010","unstructured":"Chou TC. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res. 2010;70:440\u20136.","journal-title":"Cancer Res"},{"key":"7831_CR39","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.621566","volume":"11","author":"U Kulkarni","year":"2021","unstructured":"Kulkarni U, Mathews V. Evolving chemotherapy free regimens for acute promyelocytic leukemia. Front Oncol. 2021;11:621566.","journal-title":"Front Oncol"},{"key":"7831_CR40","doi-asserted-by":"publisher","first-page":"2505","DOI":"10.1182\/blood-2007-07-102798","volume":"111","author":"ZY Wang","year":"2008","unstructured":"Wang ZY, Chen Z. Acute promyelocytic leukemia: from highly fatal to highly curable. Blood. 2008;111:2505\u201315.","journal-title":"Blood"},{"key":"7831_CR41","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.610820","volume":"10","author":"M Molica","year":"2020","unstructured":"Molica M, Mazzone C, Niscola P, de Fabritiis P. TP53 mutations in acute myeloid leukemia: still a daunting challenge?. Front Oncol. 2020;10:610820.","journal-title":"Front Oncol"},{"key":"7831_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2023.101108","volume":"4","author":"AL Boyd","year":"2023","unstructured":"Boyd AL, Lu J, Hollands CG, Alsostovar L, Murali S, Reid JC, et al. Leukemic progenitor compartment serves as a prognostic measure of cancer stemness in patients with acute myeloid leukemia. Cell Rep Med. 2023;4:101108.","journal-title":"Cell Rep Med"},{"key":"7831_CR43","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.899502","volume":"12","author":"M Peng","year":"2022","unstructured":"Peng M, Huang Y, Zhang L, Zhao X, Hou Y. Targeting mitochondrial oxidative phosphorylation eradicates acute myeloid leukemic stem cells. Front Oncol. 2022;12:899502.","journal-title":"Front Oncol"},{"key":"7831_CR44","doi-asserted-by":"publisher","first-page":"3173","DOI":"10.1182\/blood-2007-05-092510","volume":"111","author":"A Sallmyr","year":"2008","unstructured":"Sallmyr A, Fan J, Datta K, Kim KT, Grosu D, Shapiro P, et al. Internal tandem duplication of FLT3 (FLT3\/ITD) induces increased ROS production, DNA damage, and misrepair: implications for poor prognosis in AML. Blood. 2008;111:3173\u201382.","journal-title":"Blood"},{"key":"7831_CR45","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.3390\/antiox9121188","volume":"9","author":"J Van Loenhout","year":"2020","unstructured":"Van Loenhout J, Peeters M, Bogaerts A, Smits E, Deben C. Oxidative stress-inducing anticancer therapies: taking a closer look at their immunomodulating effects. Antioxidants. 2020;9:1188.","journal-title":"Antioxidants"},{"key":"7831_CR46","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-02915-8","volume":"9","author":"H Wang","year":"2018","unstructured":"Wang H, Gao Z, Liu X, Agarwal P, Zhao S, Conroy DW, et al. Targeted production of reactive oxygen species in mitochondria to overcome cancer drug resistance. Nat Commun. 2018;9:562.","journal-title":"Nat Commun"},{"key":"7831_CR47","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1038\/s41392-022-01231-4","volume":"8","author":"H Xu","year":"2023","unstructured":"Xu H, Zhao H, Ding C, Jiang D, Zhao Z, Li Y, et al. Celastrol suppresses colorectal cancer via covalent targeting peroxiredoxin 1. Signal Transduct Target Ther. 2023;8:51.","journal-title":"Signal Transduct Target Ther"},{"key":"7831_CR48","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1038\/s41416-018-0263-y","volume":"119","author":"M Bajor","year":"2018","unstructured":"Bajor M, Zych AO, Graczyk-Jarzynka A, Muchowicz A, Firczuk M, Trzeciak L, et al. Targeting peroxiredoxin 1 impairs growth of breast cancer cells and potently sensitises these cells to prooxidant agents. Br J Cancer. 2018;119:873\u201384.","journal-title":"Br J Cancer"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-07831-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-07831-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-07831-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T08:27:31Z","timestamp":1757406451000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-07831-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,18]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["7831"],"URL":"https:\/\/doi.org\/10.1038\/s41419-025-07831-6","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,18]]},"assertion":[{"value":"6 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The study was approved by the Ethics Committee of Shenzhen University Medical School (Approval Number: PN-2022-001). All procedures were performed in accordance with the Declaration of Helsinki. Informed consent was obtained from all participants for the use of tissue samples and clinical data in experiments and for publication.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}],"article-number":"627"}}